The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis

Silva, Danielle Soares de Oliveira Daian e; Fonseca, Flávio Guimarães da

doi:10.3390/vaccines9101101

Cited by 12 publications

(8 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data reported the ability of the vaccine to produce a heterologous protein capable of being recognized by the serum of animals naturally infected with FIV. These results corroborate that MVA is a vector capable of being engineered to produce heterologous proteins with the correct folding in mammal systems, which was extensively studied and reviewed elsewhere [ 33 , 34 , 35 , 36 ].…”

Section: Discussionsupporting

confidence: 83%

Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector

et al. 2022

View full text Add to dashboard Cite

The feline immunodeficiency virus (FIV) is a retrovirus with global impact and distribution, affecting both domestic and wild cats. This virus can cause severe and progressive immunosuppression culminating in the death of felids. Since the discovery of FIV, only one vaccine has been commercially available. This vaccine has proven efficiency against FIV subtypes A and D, whereas subtype B (FIV-B), found in multiple continents, is not currently preventable by vaccination. We, therefore, developed and evaluated a vaccine prototype against FIV-B using the recombinant viral vector modified vaccinia virus Ankara (MVA) expressing the variable region V1–V3 of the FIV-B envelope protein. We conducted preclinical tests in immunized mice (C57BL/6) using a prime-boost protocol with a 21 day interval and evaluated cellular and humoral responses as well the vaccine viability after lyophilization and storage. The animals immunized with the recombinant MVA/FIV virus developed specific splenocyte proliferation when stimulated with designed peptides. We also detected cellular and humoral immunity activation with IFN-y and antibody production. The data obtained in this study support further development of this immunogen and testing in cats.

show abstract

Section: Discussionsupporting

confidence: 83%

Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The better route of administration and frequency of booster dose administration is under investigation. The Oxford-AstraZeneca vaccine would be less effective against the beta variant, and the prospect of a “booster” dose for persons who have previously been vaccinated toward COVID-19 has been mentioned [ 190 ].…”

Section: Booster Dose Strategymentioning

confidence: 99%

Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status

et al. 2023

View full text Add to dashboard Cite

The coronavirus disease (COVID-19) breakout had an unimaginable worldwide effect in the 21st century, claiming millions of lives and putting a huge burden on the global economy. The potential developments in vaccine technologies following the determination of the genetic sequence of SARS-CoV-2 and the increasing global efforts to bring potential vaccines and therapeutics into the market for emergency use have provided a small bright spot to this tragic event. Several intriguing vaccine candidates have been developed using recombinant technology, genetic engineering, and other vaccine development technologies. In the last decade, a vast amount of the vaccine development process has diversified towards the usage of viral vector-based vaccines. The immune response elicited by such vaccines is comparatively higher than other approved vaccine candidates that require a booster dose to provide sufficient immune protection. The non-replicating adenoviral vectors are promising vaccine carriers for infectious diseases due to better yield, cGMP-friendly manufacturing processes, safety, better efficacy, manageable shipping, and storage procedures. As of April 2022, the WHO has approved a total of 10 vaccines around the world for COVID-19 (33 vaccines approved by at least one country), among which three candidates are adenoviral vector-based vaccines. This review sheds light on the developmental summary of all the adenoviral vector-based vaccines that are under emergency use authorization (EUA) or in the different stages of development for COVID-19 management.

show abstract

“…This vaccine contains replication-defective Ad5 vectors expressing the full-length spike gene based on Wuhan-Hu-1. The phase I and II trials results suggest that this vaccine demonstrated a good safety profile [ 8 , 9 , 10 ]. Despite this information, the lack of authorization by the WHO for the Ad5-nCov vaccine generates uncertainty in the population; thus, it is important to gain more knowledge about the immunogenicity, efficacy, duration of protection, and side effects to contribute to an informed decision-making process for the health authorities.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study

et al. 2022

View full text Add to dashboard Cite

Several studies have reported the benefits and safety of heterologous vaccination among different approved vaccines; however, there are no specific reports on the effects of vaccination with the Ad5-nCoV and other vaccines of the same or different technologies. In the present study, we evaluated the neutralizing antibodies percentage against SARS-CoV-2 in Mexican patients immunized with the Ad5-nCoV vaccine six months after its application. Moreover, the effect of the heterologous vaccination with the Ad5-nCoV vaccine and a booster dose of ChAdOx1-S-Nov-19, Ad26.COV2.S, BNT162b2, or mRNA-127 were determined. Our results suggest that a heterologous regimen of one dose with Ad5-nCoV vaccine followed by a booster dose of a different vaccine is safe and induces a stronger humoral immune response.

show abstract

The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis

Cited by 12 publications

References 85 publications

Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector

Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector

Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status

Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study

Contact Info

Product

Resources

About